Important advances in oncology最新文献_第7页

Genetic basis of renal cell cancer. 肾细胞癌的遗传基础。

Important advances in oncology Pub Date : 1993-01-01

W M Linehan, J R Gnarra, M I Lerman, F Latif, B Zbar

引用次数: 0

Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia. 视黄酸及其重排受体在急性早幼粒细胞白血病治疗中的作用。

Important advances in oncology Pub Date : 1993-01-01

W H Miller, E Dmitrovsky

{"title":"Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia.","authors":"W H Miller, E Dmitrovsky","doi":"","DOIUrl":"","url":null,"abstract":"APL is a unique clinical example where a defined molecular genetic defect appears involved in both the pathogenesis and treatment of a human leukemia. The consistent finding that RA induces remissions in APL is especially notable, since treatment involves an oral formulation of RA. The clinical responses are linked to leukemic cell maturation, suggesting a noncytotoxic mechanism of RA action. This provides a rationale for combining cytotoxic and cytodifferentiation agents in future clinical trials. Despite high initial CR rates with continuous RA therapy, relapses frequently occur. Pharmacologic mechanisms of resistance to RA therapy are implicated in clinical resistance. Future work will explore if this resistance can be overcome and how genetic mechanisms contribute to clinical RA resistance in APL. The exciting convergence of clinical and basic information in PL has led to new insights into the molecular nature of this leukemia. The discovery that RAR-alpha is rearranged in the t(15,17) provides an opportunity to study how this rearrangement is involved in oncogenesis and treatment response in APL. The application of RT-PCR assays for this molecular rearrangement will be useful in the diagnosis and subsequent tailoring of postremission therapy in APL. Whether APL serves as a paradigm for cytodifferentiation therapy remains to be seen. However, it is encouraging that 13-cis-retinoic acid in combination with alpha interferon is an active therapy in squamous cell carcinomas of the cervix and skin. Although the mechanisms responsible for these clinical responses are unknown, they highlight the need to learn how RA works and when it should be used to treat cancer patients.","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"81-90"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19374997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Programmed cell death: Bcl-2. 程序性细胞死亡:Bcl-2。

Important advances in oncology Pub Date : 1993-01-01

S J Korsmeyer

引用次数: 0

The use of peripheral stem cell support of high-dose chemotherapy. 外周干细胞支持大剂量化疗的应用。

Important advances in oncology Pub Date : 1993-01-01

A Kessinger, J O Armitage

{"title":"The use of peripheral stem cell support of high-dose chemotherapy.","authors":"A Kessinger, J O Armitage","doi":"","DOIUrl":"","url":null,"abstract":"Blood-derived stem cells are a functionally equivalent alternative to marrow-derived stem cells when autotransplanted to restore hematopoiesis that has been iatrogenically ablated. This alternate source of stem cells is particularly useful for patients who are candidates for marrow-ablative therapy and who also have bone marrow abnormalities that make it an unsuitable product for transplantation. When autologous blood-derived stem cells that were collected while their numbers were deliberately expanded in the circulation (mobilized) are transplanted, the resultant recovery of marrow function is very rapid. Because autologous bone marrow transplantation alone cannot result in hematopoietic recovery that is as rapid, peripheral stem cells have been preferred to bone marrow for autografting in some patients. This early recovery involves not only granulocytes but also platelets and red cells. Currently available cytokines administered at the time of ABMT usually facilitate only rapid granulocyte recovery. Emerging studies indicate that other consequential benefits of peripheral stem cell infusion that have not yet been fully recognized may exist. If, ultimately, techniques are developed that produce optimal stem cell mobilization for every eligible patient, then perhaps peripheral stem cell collections can be completed in 1 to 2 days. These cells could be used to minimize or ameliorate the hematopoietic toxicity associated with myelotoxic therapy. Perhaps then the technique eventually will become a routine adjunct to chemotherapy administration.","PeriodicalId":77172,"journal":{"name":"Important advances in oncology","volume":" ","pages":"167-75"},"PeriodicalIF":0.0,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19092698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fluorescence in situ hybridization in cancer diagnosis. 荧光原位杂交在肿瘤诊断中的应用。

Important advances in oncology Pub Date : 1993-01-01

M M Le Beau

引用次数: 0

Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No. 对于何杰金氏病，循环化疗是否优于标准的四药化疗?不。

Important advances in oncology Pub Date : 1993-01-01

V T DeVita

引用次数: 0

Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphoma. 自体骨髓清除治疗非霍奇金淋巴瘤。

Important advances in oncology Pub Date : 1993-01-01

J G Gribben, L M Nadler